Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2002-10-10
2009-10-06
Campell, Bruce (Department: 1648)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023400, C424S218100
Reexamination Certificate
active
07598362
ABSTRACT:
The present invention features Ad6 vectors and a nucleic acid encoding a Met-NS3-NS4A-NS4B-NS5A-NS5B polypeptide containing an inactive NS5B RNA-dependent RNA polymerase region. The nucleic acid is particularly useful as a component of an adenovector or DNA plasmid vaccine providing a broad range of antigens for generating an HCV specific cell mediated immune (CMI) response against HCV.
REFERENCES:
patent: 5122458 (1992-06-01), Post et al.
patent: 5731172 (1998-03-01), Saito et al.
patent: 5739002 (1998-04-01), De Francesco et al.
patent: 5792462 (1998-08-01), Johnston et al.
patent: 5847101 (1998-12-01), Okayama et al.
patent: 5994083 (1999-11-01), Felici et al.
patent: 6033908 (2000-03-01), Bout et al.
patent: 6127116 (2000-10-01), Rice et al.
patent: 6156558 (2000-12-01), Johnston et al.
patent: 6511832 (2003-01-01), Guarino et al.
patent: 6544780 (2003-04-01), Wang
patent: 7049428 (2006-05-01), Rice et al.
patent: 0 173 552 (1986-03-01), None
patent: 0 173 552 (1991-10-01), None
patent: 464287 (1992-01-01), None
patent: WO 95/32733 (1995-12-01), None
patent: WO 96/37619 (1996-11-01), None
patent: WO 97/47358 (1997-12-01), None
patent: WO 98/43702 (1998-10-01), None
patent: WO 99/38880 (1999-08-01), None
patent: WO 99/52463 (1999-10-01), None
patent: WO 99/60132 (1999-11-01), None
patent: WO 01/02607 (2001-01-01), None
patent: WO 01/30812 (2001-05-01), None
patent: WO 01/38360 (2001-05-01), None
patent: WO 01/47551 (2001-07-01), None
patent: WO 02/22080 (2002-03-01), None
Danthne X. and Imperiale MJ. Production of first generation adenovirus vectors: a review. (2000) Gene Therapy, 7, pp. 1707-1714.
Takamizawa et al. Structure and organization of the Hepatitis C virus genome isolated from human carriers. Journal of Virology, 1991, vol. 65, p. 1105-1113.
Bartenschlager, R. et al. “Nonstructural Protein 3 of the Hepatitis C Virus Encodes a Serine-Type Proteinase Required for Cleavage at the NS3/4 and NS4/5 Junctions”, Journal of Virology, 1993, vol. 67, pp. 3835-3844.
Behrens, S. et al. “Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus”, The EMBO Journal, 1996, vol. 15, pp. 12-22.
Bett, A. et al. “Packaging Capacity and Stability of Human Adenovirus Type 5 Vectors”, Journal of Virology, 1993, vol. 67, pp. 5911-5921.
Brenner, M. “Gene Transfer by Adenovectors”, Blood, 1999, vol. 94, pp. 3965-3967.
Chamberlain, B. et al. “Complete nucleotide sequence of type 4 hepatitis C virus variant, the predominant genotype in the Middle East”, Journal of General Virology, 1997, vol. 78, pp. 1341-1347.
Chapman, B. et al. “Effect of intron A from cytomegalovirus (Towne) immediate-early gene on hterologous expression in mammalian cells”, Nucleic Acids Research, 1991, vol. 19, pp. 3979-3986.
Chartier, C. et al. “Efficient Generation of Recombinant Adenovirus Vectors by Homologous Recombinaation inEscherichia coli”, Journal of Virology, 1996, vol. 70, pp. 4805-4810.
Cho, J. et al. “Enhanced cellular immunity to hepatitis C virus nonstructural proteins by codelivery of granulocyte macrophage-colony stimulating factor gene in intramuscular DNA immunization”, Vaccine, 1999, vol. 17, pp. 1136-1144.
Choo, Q. et al. “Isolation of a cDNA Clone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome”, Science, 1989, vol. 244, pp. 359-362.
Chroboczek, J. et al. “The Sequence of the Genome of Adenovirus Type 5 and Its Comparison with the Genome of Adenovirus Type 2”, Virology, 1992, vol. 186, pp. 280-285.
Chung, J. et al. A 5′ Element of the Chicken B-Globin Domain Serves as an Insulator in Human Erythroid Cells and Protects against Position Effect inDrosophila, Cell, 1993, vol. 74, pp. 505-514.
Danthinne, X. et al. “Production of first generation adenovirus vectors: a review”, Gene Therapy, 2000, vol. 7, pp. 1707-1714.
De Francesco, R. et al. “Biochemical and Immunologic Properties of the Nonstructural Proteins of the Hepatitis C Virus: Implications for Development of Antiviral Agents and Vaccines”, Seminars in Liver Disease, 2000, vol. 20, pp. 69-83.
Donnelly, J. et al. “DNA Vaccines”, Annual Review of Immunology, 1997, vol. 15, pp. 617-648.
Donnelly, J. et al. “Minireview DNA Vaccines” Life Sciences, 1997, vol. 60, pp. 163-172.
Failla, C. et al. “Both NS3 and NS4A Are Required for Proteolytic Processing of Hepatitis C Virus Nonstructural Proteins”, Journal of Virology, 1994, vol. 68, pp. 3753-3760.
Fallaux, F. et al. “New Helper Cells and Matched Early Region 1-Deleted Adenovirus Vectors Prevent Generation of Replication-Competent Adenoviruses”, Human Gene Therapy, 1998, vol. 9, pp. 1909-1917.
Foecking, M. et al. “Powerful and versatile enhancer-promoter unit for mammalian expression vectors”, Gene, 1986, vol. 45, pp. 101-105.
Gilbert, S et al. “Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model usinga recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes”, Vaccine, 2002, vol. 20, pp. 1039-1045.
Graham, F. et al. “Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5”, Journal General Virology, 1977, vol. 36, pp. 59-74.
Graham, F. “Covalently closed circles of human adenovirus DNA are infectious”, The EMBO Journal, 1984, vol. 3, pp. 2917-2922.
Grakoui, A. et al. “A second hepatitis C virus-encoded proteinase”, Proc. Natl. Acad. Sci. USA, 1993, vol. 90, pp. 10583-10587.
Grakoui, A. et al. “Expression and Identification of Hepatitis C Virus Polyprotein Cleavage Products”, Journal of Virology, 1993, vol. 67, pp. 1385-1395.
Hagstrom, J. et al. “Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter”, Blood, 2000, vol. 95, pp. 2536-2542.
Hijikata, M. et al.. “Proteolytic processing and membrane association of putative monstructural proteins of hepatitis C virus”, Proc. Natl. Acad. Sci. USA, 1993, vol. 90, pp. 10773-10777.
Hitt, M. et al. “Human Adenovirus Vectors for Gene Transfer into Mammalian Cells”, Advances in Pharmacology, 1997, vol. 40, pp. 137-206.
Hitt, M. et al. “Techniques of Human Adenovirus Vector Construction and Characterization”, Methods in Molecular Genetics, 1995, vol. 7, pp. 13-30.
Kolykhalov, A. et al. “Hepatits C Virus-Encoded Enzymatic Activities and Conserved RNA Elements in the 3′ Nontranslated Region Are Essential for Virus Replication In Vivo”, Journal of Virology, 2000, vol. 74, pp. 2046-2051.
Kozak, M. “Point Mutations Define a Sequence Flanking the AUG Initiator Codon That Modulates Translation by Eukaryotic Ribosomes”, Cell, 1986, vol. 44, pp. 283-292.
Kuo, G. et al. “An Assay for Circulating Antibodies to a Major Etiologic Virus of Human Non-A, Non-B Hepatitis”, Science, 1989, vol. 244, pp. 362-364.
Lechner, F. et al. “Analysis of Successful Immune Responses in Persons Infected with Hepatitis C Virus”, Journal of Experimental Medicine, 2000, vol. 9, pp. 1499-1512.
Li, X. et al. “Synthetic muscle promoters: activities exceeding naturally occuring regulatory sequences”, Nature Biotechnology, 1999, vol. 17, pp. 241-245.
Lohmann, V. et al. “Biochemical and Kinetic Analysesof NS5B RNA-Dependent Poymerase of the Hepatitis C Virus”, Virology, 1998, vol. 249, pp. 108-118.
Lohmann, V. et al. “Biochemical Properties of Hepatitis C Virus NS5B RNA-Dependent RNA Polymerase and Identification of Amino Acid Seqeunce Motifs Essential for Enzymatic Activity”, Journal of Virology, 1997, vol. 71, pp. 8416-8428.
Mizushima, H. et al. “Analysis of N-Terminal Processing of Hepatitis C Virus Nonstructural Protein 2”, Journal of Virology, 1994, vol. 68, pp. 2731-2734.
Montgomery, D. et al. “Heterologous and Homologous P
Bett Andrew J.
Colloca Stefano
Cortese Riccardo
Emini Emilio A.
Kaslow David C.
Boesen Agnieszka
Campell Bruce
Heber Sheldon O.
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.A.
Merck & Co. , Inc.
LandOfFree
Hepatitis C virus vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hepatitis C virus vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hepatitis C virus vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4140104